How women-led innovators are driving global expansion

Tern plc

Scotland is on the cusp of a transformative economic shift, fuelled by the rise of women-led businesses poised to unlock billions in untapped export potential. At the forefront of this movement is Talking Medicines, a Glasgow-based healthtech company redefining the boundaries of AI-driven healthcare marketing. Their recent participation in the “Promoting Women-Led Businesses to Export” roundtable underscores a broader narrative: female entrepreneurs are not just contributing to Scotland’s economy—they are reshaping its global footprint.

On 1st May 2025, Talking Medicines’ Co-Founder and COO/CDO, Dr Elizabeth Fairley, represented the company at a pivotal roundtable hosted by the Scotland Office and led by MP Kirsty McNeill. The event convened a dynamic group of female entrepreneurs, investors, and policymakers to address the challenges and opportunities facing women-led enterprises in international markets. Discussions centred on enhancing access to finance, fostering cross-border collaborations, and leveraging Scotland’s robust support infrastructure to scale globally.

Talking Medicines exemplifies the success achievable when innovation meets opportunity. Their flagship product, Drug-GPT, harnesses advanced data science and AI to transform unstructured healthcare data into actionable insights, revolutionising how pharmaceutical companies engage with healthcare professionals and patients. This cutting-edge approach has not only garnered industry acclaim but also positioned the company as a leader in the burgeoning field of healthcare conversational intelligence.

The company’s strategic expansion into the U.S. market, bolstered by participation in Scottish Enterprise’s Market Booster programme, highlights the scalability of their model. With operations established in key American hubs, Talking Medicines is leveraging transatlantic partnerships to accelerate growth and innovation. This international trajectory underscores the critical role of supportive ecosystems in enabling women-led businesses to thrive on the global stage.

However, the broader landscape reveals significant disparities. Research indicates that if women-led businesses in Scotland exported at the same rate as their male counterparts, the nation’s trade could increase by £3.4 billion to £10.3 billion over two years . Addressing this “gender export gap” requires targeted interventions, including tailored export training programmes and inclusive trade missions, to empower female entrepreneurs to navigate and penetrate international markets effectively.

Talking Medicines’ journey illustrates the profound impact of aligning innovative solutions with strategic support. Their commitment to fostering gender diversity within their leadership and operational teams not only drives internal excellence but also serves as a blueprint for sustainable growth. By championing inclusivity and leveraging Scotland’s entrepreneurial resources, they are setting a precedent for how women-led businesses can achieve and sustain global success.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Tern Plc launches £509,368 underwritten Open Offer

Tern Plc has announced an underwritten Open Offer to raise approximately £509,368 through the issue of 56.6 million shares at 0.90p each. Qualifying shareholders may subscribe for one new share for every 16 shares held, with the offer closing on 22 September 2026.

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.

Talking Medicines builds its AI strategy around specialist life sciences intelligence

Talking Medicines is positioning specialist healthcare intelligence as the core layer that gives agentic AI useful context in life sciences.

Search